On Nov. 15, 2020, Johnson & Johnson announced that it continued to enroll and vaccinate study participants for the Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for prevention of COVID-19 being developed by the Janssen Pharma.